RU2606622C2 - Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств - Google Patents

Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств Download PDF

Info

Publication number
RU2606622C2
RU2606622C2 RU2013113634A RU2013113634A RU2606622C2 RU 2606622 C2 RU2606622 C2 RU 2606622C2 RU 2013113634 A RU2013113634 A RU 2013113634A RU 2013113634 A RU2013113634 A RU 2013113634A RU 2606622 C2 RU2606622 C2 RU 2606622C2
Authority
RU
Russia
Prior art keywords
compound according
disease
pharmaceutically acceptable
compound
cells
Prior art date
Application number
RU2013113634A
Other languages
English (en)
Russian (ru)
Other versions
RU2013113634A (ru
Inventor
Пабло ВИЛЛОСЛАДА
Анхель МЕССЕГУЭР
Original Assignee
Бионуре Фарма, С.Л.
Институт Д’Инвестигасионс Биомедикес Аугуст Пи И Суниер (Идибапс)
Консехо Супериор Де Инвестигасионес Сьентификас (Ксис)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионуре Фарма, С.Л., Институт Д’Инвестигасионс Биомедикес Аугуст Пи И Суниер (Идибапс), Консехо Супериор Де Инвестигасионес Сьентификас (Ксис) filed Critical Бионуре Фарма, С.Л.
Publication of RU2013113634A publication Critical patent/RU2013113634A/ru
Application granted granted Critical
Publication of RU2606622C2 publication Critical patent/RU2606622C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2013113634A 2010-08-31 2011-08-31 Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств RU2606622C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37882310P 2010-08-31 2010-08-31
US61/378,823 2010-08-31
PCT/IB2011/002562 WO2012028959A1 (en) 2010-08-31 2011-08-31 Agonists of neurotrophin receptors and their use as medicaments

Publications (2)

Publication Number Publication Date
RU2013113634A RU2013113634A (ru) 2014-10-10
RU2606622C2 true RU2606622C2 (ru) 2017-01-10

Family

ID=45048148

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013113634A RU2606622C2 (ru) 2010-08-31 2011-08-31 Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств

Country Status (19)

Country Link
US (3) US8791076B2 (enExample)
EP (1) EP2611775B8 (enExample)
JP (1) JP5946454B2 (enExample)
KR (1) KR101964954B1 (enExample)
CN (1) CN103270022B (enExample)
AU (1) AU2011298091B2 (enExample)
BR (1) BR112013004662B8 (enExample)
CA (1) CA2809774C (enExample)
DK (1) DK2611775T3 (enExample)
ES (1) ES2575684T3 (enExample)
HR (1) HRP20160553T1 (enExample)
HU (1) HUE029393T2 (enExample)
IL (1) IL224972A (enExample)
MX (1) MX340233B (enExample)
PL (1) PL2611775T3 (enExample)
PT (1) PT2611775E (enExample)
RU (1) RU2606622C2 (enExample)
SI (1) SI2611775T1 (enExample)
WO (1) WO2012028959A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11518763B2 (en) 2018-12-05 2022-12-06 Scohia Pharma, Inc. Macrocyclic compound and use thereof
RU2798235C2 (ru) * 2018-12-05 2023-06-19 Скохиа Фарма, Инк. Макроциклическое соединение и его применение

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
AU2011298091B2 (en) 2010-08-31 2015-08-20 Accure Therapeutics, S.L. Agonists of neurotrophin receptors and their use as medicaments
WO2014100433A1 (en) * 2012-12-19 2014-06-26 Brown University Methods for treatment of microcephaly associated autism disorders
EP2950095B1 (en) * 2014-05-28 2018-08-29 Technische Universität Dresden Cell-based assay and screening methods for modulators of p75NTR signaling
WO2018039641A1 (en) * 2016-08-25 2018-03-01 Pharmatrophix, Inc. Methods and compounds for treating alcohol use disorders and associated diseases
KR101821118B1 (ko) 2016-09-06 2018-01-23 가톨릭대학교 산학협력단 감보그 산(gambogic acid)을 포함한 알러지성 질환 예방 또는 치료용 조성물
CN107802823A (zh) * 2017-10-27 2018-03-16 胡军 Sh2b衔接蛋白1在治疗帕金森病中的功能应用
JP2021530507A (ja) * 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
JP2022548337A (ja) * 2019-09-03 2022-11-17 ピーター ジェイ． シークマイヤー， グルタミン酸受容体アゴニストにより認知機能を増加させる方法
TW202131914A (zh) * 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 用於神經疾病或病狀的治療之新治療方案
JPWO2023190675A1 (enExample) 2022-03-30 2023-10-05
IL321571A (en) * 2022-12-22 2025-08-01 Oculis Operations S?Rl Synthesis of small molecules that are agonists for neurotrophins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1338604A1 (en) * 2000-10-06 2003-08-27 Diverdrugs, S.L. N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing said trimeres
RU2009105176A (ru) * 2009-02-16 2010-08-27 Учреждение Российской Академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова (RU) Дипептидные миметики нейротрофинов ngf и bdnf

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU189214B (en) 1983-01-20 1986-06-30 Alkaloida Vegyeszeti Gyar,Hu Process for preparing pyrroline and pyrrolidine carboxamide derivatives
US6271205B1 (en) 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US5747458A (en) 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6391871B1 (en) 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
CZ304308B6 (cs) 2000-05-04 2014-02-26 Basf Aktiengesellschaft Fenylsulfamoylové karboxamidy, substituované uracilem, způsob jejich přípravy a herbicidní kompozice s jejich obsahem
ES2169691B1 (es) * 2000-10-11 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.
CA2506850C (en) 2002-11-20 2014-05-13 Neuronova Ab Compounds and methods for increasing neurogenesis
DE10303229B4 (de) 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
US20110052603A1 (en) 2006-10-06 2011-03-03 The Walter And Eliza Hall Institute Of Medical Research method of treatment and agents useful for same
EP1994944A1 (en) * 2007-05-21 2008-11-26 Laboratorios SALVAT, S.A. Polymer conjugate compounds for the inhibition of apoptosis
JP5602020B2 (ja) 2008-09-24 2014-10-08 株式会社リボミック Ｎｇｆに対するアプタマー及びその使用
EP2289882A1 (en) 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
AU2011298091B2 (en) 2010-08-31 2015-08-20 Accure Therapeutics, S.L. Agonists of neurotrophin receptors and their use as medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1338604A1 (en) * 2000-10-06 2003-08-27 Diverdrugs, S.L. N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing said trimeres
RU2009105176A (ru) * 2009-02-16 2010-08-27 Учреждение Российской Академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова (RU) Дипептидные миметики нейротрофинов ngf и bdnf

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11518763B2 (en) 2018-12-05 2022-12-06 Scohia Pharma, Inc. Macrocyclic compound and use thereof
RU2798235C2 (ru) * 2018-12-05 2023-06-19 Скохиа Фарма, Инк. Макроциклическое соединение и его применение
RU2798235C9 (ru) * 2018-12-05 2023-09-20 Скохиа Фарма, Инк. Макроциклическое соединение и его применение

Also Published As

Publication number Publication date
RU2013113634A (ru) 2014-10-10
EP2611775A1 (en) 2013-07-10
US8791076B2 (en) 2014-07-29
AU2011298091B2 (en) 2015-08-20
US20170121367A1 (en) 2017-05-04
WO2012028959A1 (en) 2012-03-08
JP2013536833A (ja) 2013-09-26
KR20130106384A (ko) 2013-09-27
PL2611775T3 (pl) 2016-11-30
HRP20160553T1 (hr) 2016-09-23
CN103270022A (zh) 2013-08-28
CA2809774C (en) 2019-03-05
US20150005239A1 (en) 2015-01-01
MX340233B (es) 2016-07-01
CA2809774A1 (en) 2012-03-08
EP2611775B1 (en) 2016-03-16
KR101964954B1 (ko) 2019-04-03
JP5946454B2 (ja) 2016-07-06
ES2575684T3 (es) 2016-06-30
US9453047B2 (en) 2016-09-27
DK2611775T3 (en) 2016-06-27
BR112013004662A2 (pt) 2016-08-02
IL224972A (en) 2015-05-31
SI2611775T1 (sl) 2017-01-31
MX2013002329A (es) 2013-07-29
US10106577B2 (en) 2018-10-23
AU2011298091A1 (en) 2013-04-18
HUE029393T2 (en) 2017-03-28
BR112013004662B8 (pt) 2021-12-28
CN103270022B (zh) 2015-08-19
BR112013004662B1 (pt) 2021-09-28
EP2611775B8 (en) 2016-06-08
PT2611775E (pt) 2016-06-07
US20120052094A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
RU2606622C2 (ru) Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств
AU2012249397B2 (en) Methods of treating Alzheimer's disease, Huntington's disease, autism, or other disorders
RU2621049C2 (ru) Модуляторы рецептора нмда и их применение
Bracci-Laudiero et al. NGF in early embryogenesis, differentiation, and pathology in the nervous and immune systems
AU2015352182B2 (en) Neurodegenerative disorders
US20120237552A1 (en) Peptoid Agonists of Nerve Growth Factor and Their Use as Medicaments
EP2289882A1 (en) 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments
RU2816919C1 (ru) Искусственный пептид для лечения черепно-мозговой травмы
JP7142284B2 (ja) 神経伸長促進剤
HK40034037A (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
T CAMENTS neuroprotection is to prevent or minimize the effects of an original damage to the nervous system, or to prevent or minimize the consequences of endogenous or
Moreno et al. 3-Oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments
Hemachandra Synthesis and biological evaluation of potential CGRP antagonists: application to chronic pain

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant